JWH-073

JWH-073 is a synthetic cannabinoid in the naphthoylindole family. It is the butyl-chain analogue of JWH-018 and acts as an agonist at CB₁ and CB₂ cannabinoid receptors. JWH-073 was identified in herbal smoking mixtures in the late 2000s and became one of the more frequently detected first-generation synthetic cannabinoids. Laboratory studies show THC-like activity in animals, while metabolism research has identified several active hydroxylated metabolites.

Chemistry and history

JWH-073 is 1-butyl-3-(1-naphthoyl)indole. Its structure contains an indole ring, a butyl group attached to the indole nitrogen and a naphthoyl group at the 3-position. It differs from JWH-018 by having a four-carbon butyl chain rather than a five-carbon pentyl chain.

JWH-073 was detected in commercial herbal smoking products such as Spice and K2. US forensic laboratories reported a sharp increase in identifications between 2009 and 2011, followed by a decline as legislation and market composition changed. The DEA’s 2019 fact sheet notes that the compound has no recognised use outside research and is controlled in the United States (DEA: JWH-073 fact sheet, 2019).

Pharmacology

JWH-073 binds to both CB₁ and CB₂ receptors. One comparative study reported a CB₁ Ki of 8.9 nM and a CB₂ Ki of 38 nM, indicating greater affinity for CB₁ in that assay. Animal experiments found THC-like effects, including reduced locomotor activity, antinociception and hypothermia (Banister and colleagues, 2015).

JWH-073 is a high-efficacy cannabinoid agonist in functional assays. Its effects are not necessarily equivalent to those of THC, which generally acts as a partial agonist. This difference is relevant when interpreting the adverse reactions associated with synthetic cannabinoid products (Pharmacological and toxicological effects of synthetic cannabinoids and their metabolites, 2017).

Metabolism

Human and animal studies have identified extensive metabolism through mono- and dihydroxylation, carboxylation, N-dealkylation and combinations of these reactions. Monohydroxylated metabolites are prominent in human urine. Several retain nanomolar CB₁ affinity and can activate the receptor in vitro, so metabolism does not immediately eliminate all cannabinoid activity (Grigoryev and colleagues, 2011; Metabolite pharmacology review, 2017).

Reported effects and clinical concerns

Products containing JWH-073 have been associated with cannabis-like intoxication, but the clinical effects of synthetic cannabinoid mixtures can be more severe and less predictable. Reports involving this wider group include anxiety, confusion, agitation, vomiting, tachycardia, seizures and reduced consciousness. Many clinical cases involve mixtures or uncertain product contents, making it difficult to attribute an individual reaction to JWH-073 alone.

No controlled human study defines a typical JWH-073 experience or reliably links concentration to toxicity. The DEA fact sheet also notes that short- and long-term health effects had not been evaluated in humans.

Toxicity and research limitations

JWH-073 has a better documented forensic history than many later synthetic cannabinoids, but important gaps remain. Human pharmacokinetics are not fully characterised, and active metabolites complicate the interpretation of biological samples. Product-to-product variation and co-exposure to other substances are additional limitations in clinical reports.

Related compounds

JWH-073 is related to JWH-018, JWH-007 and AM-2201. It is the N-butyl homologue of JWH-018, while AM-2201 carries a terminal fluorine on the pentyl chain.